Anti-integrin therapy for retinovascular diseases
| dc.contributor.author | Bhatwadekar, Ashay D. | |
| dc.contributor.author | Kansara, Viral | |
| dc.contributor.author | Luo, Qianyi | |
| dc.contributor.author | Ciulla, Thomas | |
| dc.contributor.department | Ophthalmology, School of Medicine | en_US |
| dc.date.accessioned | 2021-09-09T15:14:21Z | |
| dc.date.available | 2021-09-09T15:14:21Z | |
| dc.date.issued | 2020 | |
| dc.description.abstract | Integrins are a family of multi-functional cell-adhesion molecules, heterodimeric receptors that connect extracellular matrix (ECM) to actin cytoskeleton in the cell cortex, thus regulating cellular adhesion, migration, proliferation, invasion, survival, and apoptosis. Consequently, integrins play a role in inflammation, angiogenesis and fibrosis. | en_US |
| dc.eprint.version | Author's manuscript | en_US |
| dc.identifier.citation | Bhatwadekar, A. D., Kansara, V., Luo, Q., & Ciulla, T. (2020). Anti-integrin therapy for retinovascular diseases. Expert Opinion on Investigational Drugs, 29(9), 935–945. https://doi.org/10.1080/13543784.2020.1795639 | en_US |
| dc.identifier.uri | https://hdl.handle.net/1805/26603 | |
| dc.language.iso | en | en_US |
| dc.publisher | Taylor & Francis | en_US |
| dc.relation.isversionof | 10.1080/13543784.2020.1795639 | en_US |
| dc.relation.journal | Expert Opinion on Investigational Drugs | en_US |
| dc.rights | Publisher Policy | en_US |
| dc.source | Author | en_US |
| dc.subject | anti-integrin therapy | en_US |
| dc.subject | retinovascular diseases | en_US |
| dc.subject | inflammation | en_US |
| dc.title | Anti-integrin therapy for retinovascular diseases | en_US |
| dc.type | Article | en_US |